Advances in therapy can essentially be measured using two parameters; introduction of a
new agent which benefits an increased number of patients over prevailing treatments or
more selective use of an existing drug by matching it to the biologic characteristics
associated with response. In reviewing the therapeutic landscape of myelodysplastic
syndromes (MDS), both should be applied to gauge the advances in therapy. While several
new drugs are currently in clinical trials for the treatment of MDS, three drugs were approved …